Cyproterone Acetate (Androcur, BAY94-8367)
Pre-clinicalCompletedDevelopment Stage
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
Oct 18, 2021 → Dec 31, 2021
About Cyproterone Acetate (Androcur, BAY94-8367)
Cyproterone Acetate (Androcur, BAY94-8367) is a pre-clinical stage product being developed by Bayer for Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT04925180. Target conditions include Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men.
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04925180 | Pre-clinical | Completed |
| NCT00919022 | Pre-clinical | Terminated |
Competing Products
3 competing products in Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naloxegol | Kyowa Kirin | Phase 1 | 33 |
| iptacopan | Novartis | Phase 2 | 52 |
| Idelalisib | Gilead Sciences | Pre-clinical | 22 |